Lev D Bubis1, Victoria Delibasic2, Laura E Davis2, Yunni Jeong1, Kelvin Chan3, Ekaterina Kosyachkova4, Alyson Mahar5, Paul Karanicolas1, Natalie G Coburn6. 1. Division of General Surgery, Department of Surgery and Institute of Health Policy, Management, and Evaluation, University of Toronto, T2-11, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. 2. Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, Canada. 3. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. 4. My Gut Feeling, Stomach Cancer Foundation of Canada, Toronto, Canada. 5. Manitoba Centre for Health Policy and Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. 6. Division of General Surgery, Department of Surgery and Institute of Health Policy, Management, and Evaluation, University of Toronto, T2-11, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. Natalie.Coburn@sunnybrook.ca.
Abstract
BACKGROUND: Patients with metastatic gastric cancer have poor survival outcomes and may experience high symptom burden. We evaluated symptom trajectory and risk factors for increased symptom severity among metastatic gastric cancer patients during the last 6 months of life. METHODS: We conducted a retrospective cohort study among patients ≥ 18 years diagnosed with metastatic gastric cancer from January 2007 to December 2014 in the province of Ontario, Canada. We included patients who died during the study period and who reported at least one Edmonton Symptom Assessment System (ESAS) score during the last 6 months of life. We described the proportion of patients who reported moderate-to-severe symptom scores (≥ 4) by month. Multivariable logistic regression models were created to identify risk factors for moderate-to-severe symptom scores. RESULTS: Seven hundred eighty-eight eligible patients with 3286 unique symptom scores completed during their last 6 months of life were identified. The highest prevalence of moderate-to-severe scores was observed for tiredness and lack of appetite, while nausea and depression had the lowest prevalence of elevated scores. The prevalence of moderate-to-severe was consistently high for all symptoms, particularly approaching end-of-life. Timing of ESAS scores, receipt of cancer-directed therapy, urban residence, and female sex were associated with increased odds of reporting moderate-to-severe symptom scores. CONCLUSION: Patients with metastatic gastric cancer experience significant symptom burden at the end-of-life. Routine screening with patient-reported outcome tools may assist in shared decision-making and effective palliative care by ensuring patients' health status and supportive care needs are identified promptly at the time of clinical encounters.
BACKGROUND: Patients with metastatic gastric cancer have poor survival outcomes and may experience high symptom burden. We evaluated symptom trajectory and risk factors for increased symptom severity among metastatic gastric cancer patients during the last 6 months of life. METHODS: We conducted a retrospective cohort study among patients ≥ 18 years diagnosed with metastatic gastric cancer from January 2007 to December 2014 in the province of Ontario, Canada. We included patients who died during the study period and who reported at least one Edmonton Symptom Assessment System (ESAS) score during the last 6 months of life. We described the proportion of patients who reported moderate-to-severe symptom scores (≥ 4) by month. Multivariable logistic regression models were created to identify risk factors for moderate-to-severe symptom scores. RESULTS: Seven hundred eighty-eight eligible patients with 3286 unique symptom scores completed during their last 6 months of life were identified. The highest prevalence of moderate-to-severe scores was observed for tiredness and lack of appetite, while nausea and depression had the lowest prevalence of elevated scores. The prevalence of moderate-to-severe was consistently high for all symptoms, particularly approaching end-of-life. Timing of ESAS scores, receipt of cancer-directed therapy, urban residence, and female sex were associated with increased odds of reporting moderate-to-severe symptom scores. CONCLUSION: Patients with metastatic gastric cancer experience significant symptom burden at the end-of-life. Routine screening with patient-reported outcome tools may assist in shared decision-making and effective palliative care by ensuring patients' health status and supportive care needs are identified promptly at the time of clinical encounters.
Entities:
Keywords:
Gastric cancer; Health-related quality of life; Patient-reported outcomes
Authors: L Barbera; R Sutradhar; D Howell; J Sussman; H Seow; D Dudgeon; C Atzema; C Earle; A Husain; Y Liu; M K Krzyzanowska Journal: Support Care Cancer Date: 2015-02-26 Impact factor: 3.603
Authors: B Glimelius; K Ekström; K Hoffman; W Graf; P O Sjödén; U Haglund; C Svensson; L K Enander; T Linné; H Sellström; R Heuman Journal: Ann Oncol Date: 1997-02 Impact factor: 32.976
Authors: Robert Sitarz; Małgorzata Skierucha; Jerzy Mielko; G Johan A Offerhaus; Ryszard Maciejewski; Wojciech P Polkowski Journal: Cancer Manag Res Date: 2018-02-07 Impact factor: 3.989